Children with lupus nephritis who receive belimumab achieve treatment targets faster, and can taper glucocorticoids earlier, than those using standard immunotherapy, according to data published in ...

Hyderabad: IIIT Hyderabad, in collaboration with Nizam's Institute of Medical Sciences (NIMS), has released digitised ...

Hyderabad:IIIT Hyderabad (IIIT-H) and Nizam’s Institute of Medical Sciences (NIMS) have launched India’s first publicly ...

Enhancing clinical research in India with publicly accessible histopathological image datasets for cancer and kidney disease ...

Century Therapeutics (IPSC) has entered into an agreement for an investigator-initiated Phase 1/2 trial by Professors Georg Schett and Andreas ...

The use of SGLT2 vs DPP4 inhibitors was linked to reduced cardiovascular and renal risks among patients with comorbid SLE and T2D.

Kyverna Therapeutics, Inc., a leading biotechnology company focusing on autoimmune diseases, revealed its strategic priorities for the year 2025 and anticipated milestones in a recent press release on ...

Shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) have received an average rating of “Buy” from the nine research ...

Researchers identify a pathogenic subset of CD8+ memory T-cells that promote airway tissue inflammation and recurrent ...

Kidney inflammation caused by SLE is referred to as lupus nephritis (LN), and it is estimated that between 40% and 50% of all SLE patients will develop LN that requires treatment over the course ...

Treatment of lupus nephritis Treatment can be divided into an initial phase where treatment is most intense and aimed at controlling disease activity by suppressing autoimmune inflammation ...

Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the ...